PRINCETON, N.J. / Mar 06, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024.
Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET.
Lynelle Hoch, president, Cell Therapy Organization, and Wendy Short Bartie, senior vice president, U.S. Hematology and Oncology, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami Beach, Florida, on Thursday, March 14, 2024. They will answer questions about the company beginning at 8:30 a.m. ET.
Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Last Trade: | US$56.22 |
Daily Change: | -2.28 -3.90 |
Daily Volume: | 18,744,166 |
Market Cap: | US$114.130B |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB